(2021). NICE recommends acalabrutinib for chronic lymphocytic leukaemia. PharmacoEcon Outcomes News.
Chicago Style aipamena"NICE Recommends Acalabrutinib for Chronic Lymphocytic Leukaemia." PharmacoEcon Outcomes News 2021.
MLA aipamena"NICE Recommends Acalabrutinib for Chronic Lymphocytic Leukaemia." PharmacoEcon Outcomes News 2021.
Kontuz: berrikusi erreferentzia hauek erabili aurretik.